Business Description
Theriva Biologics is a US-based clinical-stage company focused on developing new treatments for cancer and related conditions where patients currently have few effective options. Its most advanced program, VCN-01, is an engineered virus designed to target and destroy tumor cells, and is being tested across multiple cancer types including pancreatic, ovarian, and head and neck cancers. The company is also advancing a pipeline of therapies aimed at protecting patients from serious complications that can arise during cancer treatment, such as gut damage and dangerous infections caused by antibiotics. Theriva operates from its headquarters in Rockville, Maryland, and works with partners including Washington University School of Medicine to advance its clinical programs.
